North Carolina is currently home to 2641 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277
Recruiting
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/28/2025
Locations: Brookview Hills Research Assoc, Winston-Salem, North Carolina
Conditions: Lupus Nephritis
Register for Updates
STRIVE Post-Market Registry Study
NCT04302272
Recruiting
This is a single-arm, prospective, multi-center, Registry study to evaluate the long-term safety and effectiveness of the Spiration Valve System (SVS) for the treatment of severe emphysema in a post-market setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Emphysema
Register for Updates
Pulmonary Hypertension Association Registry
NCT04071327
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
07/28/2025
Locations: UNC Chapel Hill, Chapel Hill, North Carolina
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Register for Updates
Cereset Research Exploratory Study
NCT03777267
Recruiting
The purpose of this study is to evaluate the use of Cereset Research to improve autonomic function in participants with symptoms of stress, anxiety, or insomnia.
Gender:
ALL
Ages:
11 years and above
Trial Updated:
07/28/2025
Locations: Wake Forest University Health Scienc\ess, Winston-Salem, North Carolina
Conditions: Neurological Diseases or Conditions, Cardiovascular Conditions After Birth, Psychophysiologic Disorders
Register for Updates
Nurturing Outreach for Understanding and Reducing Inpatient Security of Health
NCT07010289
Recruiting
Food insecurity is the lack of consistent access to the food needed for a healthy life. Food insecurity among families whose child has been hospitalized is a critical problem affecting a large, vulnerable population. The purpose of this study is to identity the most effective ways to help those families with food insecurity.
Gender:
ALL
Ages:
All
Trial Updated:
07/25/2025
Locations: Brenner Children's Hospital, Winston-Salem, North Carolina
Conditions: Food Insecurity
Register for Updates
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
NCT06965413
Recruiting
The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus (DM). The study comprises of a 4-week screening period; a 48-week core treatment period, where all participants will receive tirzepatide as background treatment and will be randomized to one... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Accellacare of Salisbury, Salisbury, North Carolina
Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Register for Updates
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384
Recruiting
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabiliz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: GSK Investigational Site, Durham, North Carolina
Conditions: Lung Diseases, Interstitial
Register for Updates
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163
Recruiting
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/25/2025
Locations: DJL Clinical Research PLLC, Charlotte, North Carolina
Conditions: Systemic Lupus Erythematosus
Register for Updates
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Greenville, North Carolina
Conditions: Non-Small Cell Lung Cancer
Register for Updates
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
NCT06096675
Recruiting
Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Sanger Heart and Vascular Institute, Charlotte, North Carolina
Conditions: Cardiac Amyloidosis
Register for Updates
Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry
NCT05851430
Recruiting
The goal of this observational registry is to assess the use and performance of Galvanize PEF technology in a real-world setting. The main questions it aims to answer are: * PEF utilization and performance * Monitor safety outcomes and inform future generation devices. Participants will undergo the PEF procedure and be followed per institutional standard of care.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/25/2025
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Soft Tissue Lesion
Register for Updates
Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers
NCT05669664
Recruiting
This phase II trial tests how well darolutamide and leuprolide acetate work in treating patients with androgen receptor positive salivary cancer that has spread from where it first started (primary site) to other places in the body (metastatic), cannot be removed by surgery (unresectable) or that has come back after a period of responding to prior therapy (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
Register for Updates